Sergio Rutella
Overview
Explore the profile of Sergio Rutella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tin E, Rutella S, Khatri I, Na Y, Yan Y, MacLean N, et al.
Blood Cancer Discov
. 2025 Feb;
PMID: 39928733
Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using...
2.
Mazziotta F, Biavati L, Rimando J, Rutella S, Borcherding N, Parbhoo S, et al.
Blood
. 2024 May;
144(11):1168-1182.
PMID: 38776511
The interplay between T-cell states of differentiation, dysfunction, and treatment response in acute myeloid leukemia (AML) remains unclear. Here, we leveraged a multimodal approach encompassing high-dimensional flow cytometry and single-cell...
3.
Lindsay J, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, et al.
Lancet Gastroenterol Hepatol
. 2024 Feb;
9(4):333-345.
PMID: 38340759
Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to...
4.
Ocadlikova D, Lussana F, Fracchiolla N, Bonifacio M, Santoro L, Delia M, et al.
Br J Haematol
. 2023 Sep;
203(4):637-650.
PMID: 37700538
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (B-ALL). Despite remarkable clinical results, the effects of blinatumomab on the host immune...
5.
Vadakekolathu J, Rutella S
Blood
. 2023 Jul;
143(26):2689-2700.
PMID: 37467496
Single-cell and spatial multimodal technologies have propelled discoveries of the solid tumor microenvironment (TME) molecular features and their correlation with clinical response and resistance to immunotherapy. Computational tools are incessantly...
6.
Manjunath H, Al Khulaifi M, Sidahmed H, Ammar A, Vadakekolathu J, Rutella S, et al.
Technol Cancer Res Treat
. 2022 Nov;
21:15330338221129710.
PMID: 36415121
The gene expression analysis of formalin-fixed paraffin-embedded (FFPE) tissues is often hampered by poor RNA quality, which results from the oxidation, cross-linking and other chemical modifications induced by the inclusion...
7.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau T, Mukhopadhyay R, et al.
J Clin Invest
. 2022 Sep;
132(21).
PMID: 36099049
BackgroundImmune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In the current study, we characterized how acute myeloid...
8.
Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana M, et al.
Clin Cancer Res
. 2022 Mar;
28(14):3141-3155.
PMID: 35349670
Purpose: The stromal and immune bone marrow (BM) landscape is emerging as a crucial determinant for acute myeloid leukemia (AML). Regulatory T cells (Treg) are enriched in the AML microenvironment,...
9.
Yau T, Vadakekolathu J, Foulds G, Du G, Dickins B, Polytarchou C, et al.
J Gastroenterol Hepatol
. 2021 Dec;
37(3):531-541.
PMID: 34931384
Background And Aim: Anti-tumor necrosis factor-α (anti-TNF-α) agents have been used for inflammatory bowel disease; however, it has up to 30% nonresponse rate. Identifying molecular pathways and finding reliable diagnostic...
10.
Alves R, Goncalves A, Rutella S, Almeida A, De Las Rivas J, Trougakos I, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638304
Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was...